Tumor suppressor designated TS10Q23.3
A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.
1. A method for determining whether a cell in a sample from a patient has homozygous loss of a genetic locus encoding a protein consisting of the amino acid sequence of SEQ ID NO:2, the method comprising:
(a) contacting said sample with a nucleic acid probe comprising at least 95 contiguous nucleotides of SEQ ID NO:20;
(b) detecting whether said probe hybridizes to a nucleic acid molecule from said cell; and
(c)(1) determining that said cell has homozygous loss of said genetic locus if there is substantially no hybridization between said probe and said nucleic acid, or
(c)(2) determining that said cell does not have homozygous loss of said genetic locus if there is substantial hybridization between said probe and said nucleic acid.
2. The method of claim 1 , further comprising determining that said patient has a poor prognosis, as compared to a reference patient whose cells do not have homozygous loss of said genetic locus, if it is determined that said cell has homozygous loss of said genetic locus.
3. The method of claim 1 , wherein said at least 95 contiguous nucleotides of SEQ ID NO:20 comprise positions 426 to 510 of SEQ ID NO:20.
4. The method of claim 2 , wherein said at least 95 contiguous nucleotides of SEQ ID NO:20 comprise positions 426 to 510 of SEQ ID NO:20.
5. The method of claim 1 , wherein said probe is contacted with said sample in an in situ hybridization assay.
6. The method of claim 2 , wherein said probe is contacted with said sample in an in situ hybridization assay.
7. The method of claim 5 , wherein said in situ hybridization assay is a FISH assay.
8. The method of claim 6 , wherein said in situ hybridization assay is a FISH assay.
9. The method of claim 1 , wherein said probe comprises the chromosomal marker D10S215.
10. The method of claim 2 , wherein said probe comprises the chromosomal marker D10S215.
11. The method of claim 6 , wherein said probe comprises the chromosomal marker D10S215.
12. The method of claim 1 , wherein said cell is a prostate tumor cell.
13. The method of claim 2 , wherein said cell is a prostate tumor cell.
14. The method of claim 4 , wherein said cell is a prostate tumor cell.
15. The method of claim 6 , wherein said cell is a prostate tumor cell.
16. The method of claim 8 , wherein said cell is a prostate tumor cell.
17. The method of claim 11 , wherein said cell is a prostate tumor cell.